Drug maker Cipla invests addl 3-M euro in German mRNA tech co Ethris

Drug maker Cipla’s wholly-owned subsidiary Cipla (EU) will invest an additional EUR 3 million through a convertible loan in Ethris GmbH , a Munich, Germany-based global leader in mRNA technology for respiratory treatments.Cipla had invested EUR 15 million in Ethris in 2022. Cipla aims to deliver innovative mRNA-based therapies, particularly targeting respiratory treatments, to patients in emerging markets.